InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,256.17
(
1.35%
)
US TECH 100
17,666.89
(
1.45%
)
Dow Jones
39,018.46
(
0.81%
)
Brent Oil
76.84
(
-0.42%
)
Bitcoin
55,948.58
(
3.63%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ash111

Send PM Follow Ignore
Followers 1053
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

ash111

Re: croptop post# 9099

Friday, 06/26/2015 11:08:36 AM

Friday, June 26, 2015 11:08:36 AM

Post# of 23979
SNGX isn't P & D clear and simple.Phase 3 Study news out recently.

SNGX Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphomahttp://www.soligenix.com/news.aspx?titleId=487

GREAT SS,low market cap:
http://www.otcmarkets.com/stock/SNGX/profile

Over MA50+MA200 http://stockcharts.com/c-sc/sc?s=sngx&p=D&b=5&g=0&i=0&r=1434336048468

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up